The S&P/ASX 200 Index (ASX: XJO) is out of form on Tuesday and on course to record a decline. At the time of writing, the benchmark index is down 0.35% to 7,466.6 points.
Four ASX shares that are falling more than most today are listed below. Here’s why they are tumbling lower:
Bubs Australia Ltd (ASX: BUB)
The Bubs share price is down 4.5% to 41 cents. Earlier this week analysts at Citi responded to this struggling infant formula company’s disappointing quarterly update by retaining its sell rating and cutting its price target down to 33 cents. Citi isn’t expecting its performance to improve greatly in the near term, especially while international borders remain closed.
Mayne Pharma Group Ltd (ASX: MYX)
The Mayne Pharma share price has fallen 4.5% to 32 cents. This morning the pharmaceutical company announced that it has been hit with an investor class action. According to the release, the class action alleges the company undertook misleading or deceptive conduct and was in breach of continuous disclosure obligations. This relates to alleged anti-competitive conduct in the United States.
Paradigm Biopharmaceuticals Ltd (ASX: PAR)
The Paradigm share price has sunk 10% to $2.00. This follows the release of an update on its Investigational New Drug (IND) application submitted to the US Food and Drug Administration (FDA) in March. The release explains that the FDA has one remaining question relating to its application. And while management is confident it can resolve this question, the market seems less convinced.
PointsBet Holdings Ltd (ASX: PBH)
The PointsBet share price has tumbled 12% to $9.95. The catalyst for this was the completion of the sports betting company’s institutional placement and entitlement offer. PointsBet has raised $81 million at $8.00 per share and a further $215.1 million at $10.00 per share. It will now push ahead with its retail entitlement offer. These funds will be used to support North American marketing and client acquisition, technology and product development, and US market access and government licensing fees.